Philogen S.p.a.

This completed Phase 1 study tested the safety and radiation exposure of a new imaging agent called 68Ga-OncoACP3 for prostate cancer. Twenty men with prostate cancer received a single injection followed by PET/CT scans to see where the tracer goes in the body and measure radiati…

This early-stage study tested a new imaging agent called 68Ga-OncoCAIX, designed to help doctors better see clear cell kidney cancer on PET/CT scans. The trial involved 20 patients with suspected kidney cancer to check if the tracer was safe and to measure how much radiation it d…